Promentis Pharmaceuticals
Milwaukee, US · Delaware corporation · 3 known investors
Biotech
Founders & leadership
DL
Daniel LawtonExecutive Officer, Director
TB
Tom BeckExecutive Officer, Director
CB
Chad BeyerExecutive Officer
KV
Klaus VeitingerExecutive Officer, Director
SS
Steve SquintoDirector
SS
Stacey SeltzerDirector
PS
Patrick Schwarz-SchuetteDirector
Investors · 3
Competitors · 4
by search overlapBuilt In20 shared keywords
Catalent19 shared keywordsCatalent is a global contract development and manufacturing organization (CDMO) that develops, manufactures and supplies pharmaceuticals, biologics, gene and cell therapies, and consumer health products. It serves pharmaceutical, biotech and consumer health companies with integrated solutions spanning small molecule, biologics, cell and gene therapy, and clinical supply.
Ziprecruiter15 shared keywords
Inven14 shared keywordsInven provides AI-powered workflows for investment and consulting firms to automatically generate company materials such as market maps, financial profiles, and competitive landscapes from structured data. The platform serves management consulting firms and investment professionals who need to produce analyst-ready documents and decks at scale.
Companies competing with Promentis Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$2.5MraisedDec 2019 · 8 investors · PharmaceuticalsRule 506(b)
▶$2.5MraisedDec 2019 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chad BeyerExecutive Officer
- Steve SquintoDirector
- Thomas BeckDirector
- Patrick Schwarz-SchuetteDirector
- Klaus VeitingerDirector
- Daniel LawtonExecutive Officer, Director
- Stacey SeltzerDirector
- Offering amount
- $6M
- Amount sold
- $2.5M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.6MraisedSep 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$17.6MraisedSep 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daniel LawtonExecutive Officer, Director
- Chad BeyerExecutive Officer
- Tom BeckExecutive Officer, Director
- Steve SquintoDirector
- Stacey SeltzerDirector
- Patrick Schwarz-SchuetteDirector
- Klaus VeitingerExecutive Officer, Director
- Offering amount
- $17.6M
- Amount sold
- $17.6M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.8MraisedOct 2016 · 8 investors · PharmaceuticalsRule 506(b)
▶$8.8MraisedOct 2016 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daniel LawtonExecutive Officer, Director
- Klaus VeitingerExecutive Officer, Director
- Steve SquintoDirector
- Tom BeckExecutive Officer, Director
- Stacey SeltzerDirector
- Patrick Schwarz-SchuetteDirector
- Chad BeyerExecutive Officer
- Offering amount
- $8.8M
- Amount sold
- $8.8M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $151.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $508.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.